SkyWest, Inc. Announces Second Quarter 2025 Results Call Date
2:30 p.m. Mountain Time
Interested parties can access the webcast at:
https://events.q4inc.com/attendee/794666333
The call-in number for US callers is 1-888-330-2455
The call-in number for international callers is 1-240-789-2717
The conference ID/Event Plus passcode is: 8322450
Please connect ten minutes before the scheduled hour to ensure a prompt starting time. If you have any questions, please contact Investor Relations at 435-634-3200.
In addition, a digital rebroadcast of the conference call will be available after 5:30 p.m. MT on July 24, 2025 through August 7, 2025 at 9:59 p.m. MT. US callers can access the rebroadcast by dialing 1-800-770-2030; international callers can access the rebroadcast by dialing 1-609-800-9909. The conference ID is 8322450#. Your participation is welcomed and appreciated.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
SailPoint Recognized as Leader in Cloud Infrastructure Entitlement Management by KuppingerCole
SailPoint Inc. (NASDAQ:SAIL) is one of the best new stocks to buy now. On June 24, SailPoint announced that it had been recognized as an Overall Leader, Product Leader, Innovation Leader, and Market Leader in the 2025 KuppingerCole Leadership Compass for Cloud Infrastructure Entitlement Management/CIEM. The report evaluates CIEM vendors based on innovation, usability, and market presence. SailPoint's performance across these categories shows the effectiveness of its enterprise-grade approach to entitlement governance within complex multi-cloud environments. A cybersecurity expert monitoring the security of the company's assets, emphasizing the importance of data protection. The increasing complexity of managing and securing entitlements across multi-cloud setups has made CIEM solutions indispensable for organizations. SailPoint CIEM caters to the needs of complex enterprises that operate in multi-cloud environments. SailPoint Inc. (NASDAQ:SAIL) delivers solutions to enable identity security for the enterprise in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. While we acknowledge the potential of SAIL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Business Wire
an hour ago
- Business Wire
Indian Aircraft Manufacturing Company Raphe mPhibr Revolutionizes Unmanned Aerial Vehicle Innovation with Dassault Systèmes' 3DEXPERIENCE Platform
VELIZY-VILLACOUBLAY, France--(BUSINESS WIRE)-- Dassault Systèmes (Euronext Paris: FR0014003TT8, today announced that Raphe mPhibr, India's most innovative aircraft manufacturing company specializing in unmanned aerial vehicles, has adopted its 3DEXPERIENCE platform to transform how aircraft systems are conceived, validated and built, substantially reducing the design cycle. Unmanned aircraft systems are emerging in light of growing applications in defense, homeland security, agriculture, logistics and infrastructure monitoring, and are expected to reach an estimated 6.5 million units in 2030. To contribute to India's goal of becoming self-reliant in aerospace and defense, Raphe mPhibr needed a new approach to integrate technology and advanced scientific principles into its design process for the engineering of next-generation UAVs with superior strength-to-weight performance and increased payload capacity. From metals to composites and electronics, Raphe mPhibr designs and builds everything under one roof. Dassault Systèmes' 3DEXPERIENCE platform significantly reduced its product development cycle while integrating physics and design for manufacturing within the design phase. One of the most compelling use cases for the 3DEXPERIENCE platform at Raphe mPhibr was during the development of its engine. Traditionally a multi-year effort, the engine development process was shortened to just three months. The platform empowered the team to redesign parts optimized for 3D manufacturing. 1 Raphe mPhibr successfully created complex composite parts through an integrated design and simulation workflow. It reduced the weight of its 4kW 2-stroke engine, which outperforms systems seven times its weight, by 700 grams (1.54 pounds), and made a strategic shift toward 3D-centric design thinking that led to more intuitive and efficient part development. The platform also enabled the team to push the boundaries of engineering by designing high-performance aerodynamic surfaces. 'Designing and manufacturing a drone is nothing less than designing and manufacturing a whole aircraft. The kind of drones we are manufacturing have 20,000 to 30,000 parts,' said Vikash Mishra, Chairman, Raphe mPhibr. 'The 3DEXPERIENCE platform allows us to think in 3D – not in straight lines, circles or squares. Biological systems that have evolved in nature – such as plants, anatomical structures and geological formations – are not made up of geometrical shapes. So, using this platform, we can design more organically and without limitations. It's the best software to create our vision.' 'Raphe mPhibr's adoption of our 3DEXPERIENCE platform shows how innovators are building tomorrow's advanced air mobility solutions with virtual twin experiences. Its focus on in-house design sets a new benchmark for engineering excellence,' said David Ziegler, Vice President, Aerospace and Defense Industry, Dassault Systèmes. 'The 3DEXPERIENCE platform combines all aspects of design, simulation and collaboration in a single environment for innovation and operational efficiency.' Raphe mPhibr recently announced it closed $100 million in funding in a round led by General Catalyst - the largest private funding round for an Indian aircraft manufacturer to date. Raphe mPhibr has a team of over 500 people and more than 100 unique intellectual property assets. Its products have logged over one million kilometers (621,371 miles) with the security forces of India. Raphe mPhibr's future roadmap includes growing its workforce, expanding its research, development and manufacturing facility, and using virtual twin experiences for lifecycle management. Dassault Systèmes' 3DEXPERIENCE platform, 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions:
Business Wire
an hour ago
- Business Wire
Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the article L. 233-8 II of the French 'Code de Commerce' and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or ' AMF ') General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') releases its total number of shares outstanding as well as its voting rights as of July 3, 2025: (1) The total number of theoretical voting rights (or 'gross' voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017. (2) The total number of exercisable voting rights (or 'net' voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at and follow us on LinkedIn and X. Information about Innate Pharma shares Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'intend,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
